Clinical Trials Browser

Phase 2 × Recruiting × Neuroendocrine Tumors × Clear all

NCT06406465 2026-04-17

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Phase 2 Recruiting

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06638931 2026-04-15

ANTARES

Phase 2 Recruiting

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther solid neoplasmSarcomaThoracic

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

NCT03412877 2026-04-14

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Phase 2 Recruiting

BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT03206060 2026-04-01

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Phase 2 Recruiting

CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT05500391 2026-03-18

SUR-CAN

Phase 2 Recruiting

CNSEndocrineGastrointestinalNETSarcoma

Carcinosarcoma, Glioma, Seminoma, Adenocarcinoma, Clear Cell, Carcinoma, Small Cell, Sex Cord-Gonadal Stromal Tumors, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Phase 2 Recruiting

Neuroendocrine Tumors

NCT04074135 2026-02-24

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

Phase 2 Recruiting

EndocrineGastrointestinalNET

von Hippel-Lindau Disease, Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT07404176 2026-02-11

TENET

Phase 2 Recruiting

Neoplasms, Neuroendocrine Tumors

NCT07151391 2026-02-10

The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)

Phase 2 Recruiting

Neuroendocrine Tumors

NCT04954820 2026-02-05

ReLUTH

Phase 2 Recruiting

Neuroendocrine Tumors, Disease Progression

NCT06926634 2025-12-17

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

Phase 2 Recruiting

Neuroendocrine Tumors

NCT04339036 2025-12-10

CapTemY90

Phase 2 Recruiting

Neuroendocrine Tumors

NCT05263050 2025-12-03

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Phase 2 Recruiting

EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

NCT06345079 2025-08-14

STOPNET

Phase 2 Recruiting

Neuroendocrine Tumors

NCT04837885 2025-07-23

LUTARTERIAL

Phase 2 Recruiting

Neoplasms, Neuroendocrine Tumors

NCT06395402 2025-07-22

LUMOD-ID

Phase 2 Recruiting

Neuroendocrine Tumors

NCT03935893 2025-07-10

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Phase 2 Recruiting

DermatologicEndocrineGastrointestinalNETOther solid neoplasmSarcomaThoracic

Turcot syndrome, Mesothelioma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Neuroendocrine Tumors, Microsatellite Instability

NCT04888481 2025-05-07

68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

Phase 2 Recruiting

Neuroendocrine Tumors

NCT05165407 2025-03-14

NESSIE

Phase 2 Recruiting

Neuroendocrine Tumors

NCT05879055 2024-12-19

A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Phase 2 Recruiting

Neuroendocrine Tumors

NCT02185443 2024-12-09

Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases

Phase 2 Recruiting

EndocrineGastrointestinalNET

Anal Canal Carcinoma, Neoplasm Metastasis, Colorectal Neoplasms, Neuroendocrine Tumors

NCT04917484 2024-12-09

DOBATOC

Phase 2 Recruiting

Neuroendocrine Tumors

NCT05554003 2024-11-18

MeTe

Phase 2 Recruiting

Frailty, Neuroendocrine Tumors

NCT04166006 2024-09-19

RaC-Ad

Phase 2 Recruiting

EndocrineHead & NeckNETSarcoma

Head and Neck Neoplasms, Sarcoma, Neuroendocrine Tumors

NCT06045260 2024-08-13

LUFOR

Phase 2 Recruiting

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT06540937 2024-08-07

Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor

Phase 2 Recruiting

Multiple Endocrine Neoplasia, Neuroendocrine Tumors

NCT05997056 2024-07-16

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Phase 2 Recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06472388 2024-06-25

EVENET

Phase 2 Recruiting

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression